External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology Aggressive Non Hodgkin Lymphoma

Aggressive Non Hodgkin Lymphoma

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Jun 14 / Roche and Genentech
Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the Phase III Pola▼-R-CHP vs R-CHOP (POLARIX) study
POLARIX is a Phase III trial of polatuzumab vedotin in combination with R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). A retrospective subgroup analysis of the clinical outcomes and genomic patterns of patients with extranodel sites of involvement is assessed in this abstract.
Oncology Aggressive non Hodgkin lymphoma EHA-2024

Sign up or login to unlock the full suite of MEDICALLY features
Jun 3 / Roche and Genentech
Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the Phase III Pola-R-CHP vs R-CHOP (POLARIX) study
POLARIX is a Phase III trial of polatuzumab vedotin in combination with R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). A retrospective subgroup analysis of the clinical outcomes and genomic patterns of patients with extranodel sites of involvement is assessed in this abstract.
Oncology Haematology Aggressive non Hodgkin lymphoma ASCO-2024

Sign up or login to unlock the full suite of MEDICALLY features
Jun 3 / Roche and Genentech
Mosunetuzumab with polatuzumab vedotin: subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL)
GO40516 is a Phase Ib/II study of mosunetuzumab in combination with polatuzumab vedotin in patients with relapsed/refractory transplant-ineligible large B-cell lymphoma. Efficacy and safety data from the analysis of primary refractory and early relapse subgroups are presented in this abstract.
Oncology Haematology Aggressive non Hodgkin lymphoma ASCO-2024
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.